Literature DB >> 21326191

Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Anne-Marie Bédard1, Jérôme Maheux, Daniel Lévesque, Anne-Noël Samaha.   

Abstract

Chronic exposure to antipsychotic medications can persistently change brain dopamine systems. Most studies on the functional significance of these neural changes have focused on motor behavior and few have addressed how long-term antipsychotic treatment might influence dopamine-mediated reward function. We asked, therefore, whether a clinically relevant antipsychotic treatment regimen would alter the incentive motivational properties of a reward cue. We assessed the ability of a Pavlovian-conditioned stimulus to function as a conditioned reward, as well as to elicit approach behavior in rats treated with haloperidol, either continuously (achieved via subcutaneous osmotic minipump) or intermittently (achieved via daily subcutaneous injections). Continuous, but not intermittent, treatment enhanced the ability of amphetamine to potentiate the conditioned reinforcing effects of a cue associated with water. This effect was not related to differences in the ability to attribute predictive value to a conditioned stimulus (as measured by conditioned approach behavior), but was potentially linked to the development of behavioral supersensitivity to amphetamine and to augmented amphetamine-induced immediate early-gene expression (c-fos and Nur77) in dorsal striatopallidal and striatonigral cells. By enhancing the ability of reward cues to control behavior and by intensifying dopamine-mediated striatopallidal and striatonigral cell activity, standard (ie, continuous) antipsychotic treatment regimens might exacerbate drug-seeking and drug-taking behavior in schizophrenia. Achieving regular but transiently high antipsychotic levels in the brain (as modeled in the intermittent condition) might be a viable option to prevent these changes. This possibility should be explored in the clinic.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21326191      PMCID: PMC3079837          DOI: 10.1038/npp.2011.10

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  79 in total

1.  Dissociating the predictive and incentive motivational properties of reward-related cues through the study of individual differences.

Authors:  Terry E Robinson; Shelly B Flagel
Journal:  Biol Psychiatry       Date:  2008-10-18       Impact factor: 13.382

Review 2.  Adherence to antipsychotic medications.

Authors:  D O Perkins
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

3.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

Authors:  S Kapur; R Zipursky; C Jones; G Remington; S Houle
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

4.  Amphetamine and cocaine induce different patterns of c-fos mRNA expression in the striatum and subthalamic nucleus depending on environmental context.

Authors:  J Uslaner; A Badiani; C S Norton; H E Day; S J Watson; H Akil; T E Robinson
Journal:  Eur J Neurosci       Date:  2001-05       Impact factor: 3.386

Review 5.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

6.  Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.

Authors:  M L Wadenberg; S Kapur; A Soliman; C Jones; F Vaccarino
Journal:  Psychopharmacology (Berl)       Date:  2000-07       Impact factor: 4.530

7.  Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain.

Authors:  G Beaudry; M C Langlois; I Weppe; C Rouillard; D Lévesque
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

8.  D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats.

Authors:  Nathalie Ginovart; Alan A Wilson; Doug Hussey; Sylvain Houle; Shitij Kapur
Journal:  Neuropsychopharmacology       Date:  2008-08-06       Impact factor: 7.853

Review 9.  Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology.

Authors:  Matcheri S Keshavan; Rajiv Tandon; Nash N Boutros; Henry A Nasrallah
Journal:  Schizophr Res       Date:  2008-09-16       Impact factor: 4.939

10.  Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.

Authors:  Daniela Fukue Fukushiro; Rita de Cassia Carvalho; Victor Proença Ricardo; Juliana do Nascimento Alvarez; Luciana Takahashi Carvalho Ribeiro; Roberto Frussa-Filho
Journal:  Brain Res Bull       Date:  2008-06-09       Impact factor: 4.077

View more
  8 in total

1.  The self-administration of rapidly delivered cocaine promotes increased motivation to take the drug: contributions of prior levels of operant responding and cocaine intake.

Authors:  Karim Bouayad-Gervais; Ellie-Anna Minogianis; Daniel Lévesque; Anne-Noël Samaha
Journal:  Psychopharmacology (Berl)       Date:  2014-04-22       Impact factor: 4.530

2.  Antipsychotics and amotivation.

Authors:  Gagan Fervaha; Hiroyoshi Takeuchi; Jimmy Lee; George Foussias; Paul J Fletcher; Ofer Agid; Gary Remington
Journal:  Neuropsychopharmacology       Date:  2015-01-08       Impact factor: 7.853

Review 3.  Neurotensin in reward processes.

Authors:  María Luisa Torruella-Suárez; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

4.  Delayed yet persistent effects of daily risperidone on activity in developing rats.

Authors:  Rachel M Stevens; Matthew A Gannon; Molly S Griffith; Mark E Bardgett
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

5.  Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.

Authors:  Monika Vinish; Ahmed Elnabawi; Jean A Milstein; Jesse S Burke; Jonathan K Kallevang; Kevin C Turek; Carien S Lansink; Istvan Merchenthaler; Aileen M Bailey; Bryan Kolb; Joseph F Cheer; Douglas O Frost
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-25       Impact factor: 5.176

6.  Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

7.  The effectiveness of treatments for cocaine dependence in schizophrenic patients: a systematic review.

Authors:  Pamela Sabioni; Anna Carolina Ramos; Jose Carlos F Galduróz
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

Review 8.  Relevance of animal models to human tardive dyskinesia.

Authors:  Pierre J Blanchet; Marie-Thérèse Parent; Pierre H Rompré; Daniel Lévesque
Journal:  Behav Brain Funct       Date:  2012-03-09       Impact factor: 3.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.